Assessing short-term and long-term security and efficacy of anterior nucleus of the thalamus deep brain stimulation for treating drug-resistant epilepsy: A systematic review and single-arm meta-analysis.
Gabriel VerlyLeonardo de Barros OliveiraThiffany Rodrigues Delfino de OliveiraSávio BatistaThiago LopesVitória CarvalhoBilly McBenedictMatheus OliveiraRaphael BertaniPedro Henrique Martins da CunhaWellingson PaivaBruno Lima PessoaPublished in: Epilepsia (2024)
Deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) is a widespread invasive procedure for treating drug-resistant epilepsy. Nonetheless, there is a persistent debate regarding the short-term and long-term efficacy and safety of ANT-DBS. Thus we conducted a systematic review and meta-analysis. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we searched PubMed, Cochrane, Embase, and Web of Science for studies treating refractory epilepsy with ANT-DBS. Short-term analysis was considered for studies with a mean follow-up of 3 years or less. The following outcomes were assessed for data extraction: procedure responders and nonresponders, increased seizure frequency, complications, and procedure-related mortality. Of 650 studies, 25 fit our inclusion criteria, involving 427 patients. Previous surgical treatments have been reported in 214 patients (50.1%) and a median average baseline seizure frequency of 64.9 monthly seizures. In the short-term analysis, we observed a proportion of 67% (95% confidence interval [CI] 54%-79%) of responders and 33% (95% CI 21%-46%) of nonresponders. In addition, 4% (95% CI 0%-9%) of the patients presented increased seizure frequency. In the long-term analysis, we observed 72% (95% CI 66%-78%) responders and 27% (95% CI 21%-34%) nonresponders. Moreover, there was a 2% (95% CI 0%-5%) increase in seizure frequency. No procedure-related mortality was reported at any follow-up. ANT-DBS effectively treats refractory epilepsy, with lasting short-term and long-term benefits. It remains safe and efficient despite complications, showing no procedure-linked fatalities, high patient responsiveness, and minimal increased seizures. Consistent results over time and low morbidity/mortality rates emphasize its worth. Further research is necessary to diminish the discrepancy among results.
Keyphrases
- deep brain stimulation
- drug resistant
- parkinson disease
- end stage renal disease
- systematic review
- meta analyses
- ejection fraction
- obsessive compulsive disorder
- newly diagnosed
- multidrug resistant
- chronic kidney disease
- temporal lobe epilepsy
- minimally invasive
- peritoneal dialysis
- risk factors
- cardiovascular events
- cardiovascular disease
- coronary artery disease
- randomized controlled trial
- adipose tissue
- cystic fibrosis
- metabolic syndrome
- pseudomonas aeruginosa
- patient reported outcomes